Alphatec Plunges 32%. A Bone-Graft Slump Hits the Spine Specialist's Stock. — Barrons.com

What happened

Alphatec stock fell 32% to $7.71 in premarket trading after the spine-surgery company missed third-quarter revenue and earnings estimates and cut its 2026 revenue outlook to about $862 million from $882 million.

Confirmed

Global impact / market context

Fewer doctors bundled Alphatec's high profit per sale bone-graft substitutes, which means each spine surgery brings in less revenue. Investors now see weaker future sales growth, and the sharp guidance cut signals management lost confidence in near-term demand.

Analyst inference

The miss came with broader industry softness that reduced mid-to-lower back surgeries. A company cutting guidance just months after reaffirming it can raise doubts about how well management sees its own pipeline, which may weigh on the stock.

Analyst inference

What to watch

1. Watch whether biologic sales stay flat this year instead of delivering the usual $15 million to $25 million boost, since fewer bundled bone-graft sales lower revenue earned per procedure. Confirmed
2. Track whether reported spine surgery volumes translate into higher revenue per procedure again, which would show doctors are choosing Alphatec's higher-priced bone-graft products alongside implants. Analyst inference
3. Monitor signs of recovery in mid-to-lower back surgery demand, because continued industry softness could force further cuts to the already lowered 2026 revenue outlook. Analyst inference

Evidence

• Original source link unavailable